Examine IBRX stock price swings, biotech earnings, technical analysis, and 2026 forecast. Is IBRX stock a buy? Assess valuation risks and immunotherapy pipeline now.
Introduction
ImmunityBio Inc. (IBRX stock) develops cancer immunotherapies and vaccines. Its lead asset ANKTIVA targets bladder cancer with T-cell activation technology.
Investors monitor IBRX stock amid FDA approvals and clinical volatility. Biotech sector rotates on trial data releases. Small-cap biotechs face funding pressures amid rising rates.
Latest stock Price & Trend
IBRX stock closed at $8.47 on March 9, 2026, per latest trading data. It declined 4.38% to $8.29 pre-market with 4.36 million shares volume. Recent range $9.80-$10.58 March 3.
Five-day trend sharply down from $12.43 February 25 peak (-17% swing). One-month volatile around $9-12 zone. Three-month uptrend from $8.32 lows holds technically.
Six-month reflects clinical catalyst cycles. Year-to-date mixed after FDA news. 52-week high $12.43; low $0.93 shows binary risk profile. Sideways chop signals wait-for-news posture.
Technical Analysis
Support critical at $8.32 February low—break targets $7.60. Resistance $10.00 psychological level caps bounces. These levels frame high-stakes binary trades.
RSI oversold territory below 30 after 17% drop. MACD bearish crossover warns further downside. 50-day moving average falling below 200-day death cross forming.
Volume exploded 80M shares February 25 confirming distribution. Biotech traders watch RSI divergence for reversal signals.
Analyst Ratings & Price Targets
5 analysts rate IBRX stock Strong Buy consensus. Average target $13.60 implies 60% upside from $8.47. Range $5.00 low to $24.00 high reflects pipeline uncertainty.
No recent downgrades despite volatility. Wall Street conviction centers on ANKTIVA commercialization. Strong Buy rating validates clinical de-risking for risk-tolerant investors.
Insider Activity
Insider transactions quiet post-FDA milestone. No large program sales flagged. Management alignment holds steady through swings.
Stable ownership implies pipeline confidence despite price action.
Valuation Analysis
Trailing P/E negative at -18.45 from -$0.46 EPS losses. Forward P/E unavailable pre-profitability. Price-to-sales astronomical 2.44B market cap over $14.74M revenue.
Revenue minimal $14.74M FY; net loss -$413.56M. 98.33M float; cash runway supports trials. Debt position manageable for development stage.
Biotech peers trade 10-20x peak sales; IBRX appears overvalued fundamentally but typical for late-stage pipeline bets.
Recent Earnings & Catalysts
Q4 results secondary to ANKTIVA FDA approval March milestone. Revenue beat low expectations; EPS miss expected. Guidance focuses on bladder cancer launch.
Commercial rollout, BCG shortage fill-rate, and Phase 3 readouts catalyze. Approval news drove February rally before profit-taking.
Bullish Case
ANKTIVA BCG combination dominates non-muscle invasive bladder cancer. $2B+ TAM with first new mechanism in 50 years. Manufacturing scale-up underway.
$12.53 2026 price target reflects peak sales potential.
Bearish Case
Manufacturing scale-up delays plague launches. Competition from established BCG players. Phase 3 pancreatic data risk in 2026.
98% revenue dependence on single approval creates binary risk.
Market Sentiment & Investor Psychology
March 2026 $14.50 puts trade $5.00 bid reflecting downside protection. Short interest elevated post-rally. Institutions steady at 30%; retail swings wildly.
Fear-dominant sentiment after 17% drop. Momentum traders exited.
Short-Term Outlook
Oversold RSI bounce candidate to $10 resistance. Manufacturing updates drive catalysts. $8.32 support break targets $7.60 quickly.
Medium to Long-Term Outlook
Triple-antigen platform diversifies pipeline. Oncology market grows 12% CAGR. Cash burn manageable through 2027 launch.
Watchlist pending commercial execution proof.
FAQ
Is IBRX stock a buy right now?
High-risk biotech play. Wait $8 support.
What is the price target for IBRX stock?
$13.60 consensus; $24 high from analysts.
What are major risks for IBRX stock?
Manufacturing delays, trial failures, dilution.
IBRX earnings outlook?
Commercial ramp 2026; profitability 2028+.
IBRX stock forecast 2026?
$12.53 end-2026 per analysts.
Suggestions
- Compare with Opendoor
- See our bladder cancer therapy forecast.
- Read Late-stage biotech valuation guide.
Conclusion
Watchlist IBRX stock. ANKTIVA approval de-risks but manufacturing execution remains critical hurdle. $13 target reasonable if launch succeeds.
Disclaimer: This article is for informational purposes only and not financial advice.